Cabozantinib versus everolimus in advanced renal cell carcinoma

BACKGROUND: Cabozantinib is an oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL; each has been implicated in metastatic renal cell carcinoma (RCC) pathobiology or development of resistance to antiangiogenic drugs. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Choueiri, Toni K., Escudier, Bernard, Powles, Thomas, Mainwaring, Paul, Rini, Brian I., Donskov, Frede, Hammers, Hans, Hutson, Thomas E., Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J., Bjarnason, Georg A., Géczi, Lajos, Keam, Bhumsuk, Moroto, Pablo, Heng, Daniel Y. C., Schmidinger, Manuela, Kantoff, Philip W., Borgman, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M., Tannir, Nizar M., Motzer, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5024539/
https://ncbi.nlm.nih.gov/pubmed/26406150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1510016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados